Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance
NCT02931383 on ClinicalTrials.gov · last registry update 2019-03-25
An unusually large phase 4: 150 participants, more than double the 75 typical for the stage. The sponsor logged completion for February 2019. Primary outcome, as filed: Change in the degree of inflammation in the knee-joint (Greyscale-score). liraglutide is approved in the US, but not for osteoarthritis — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Henrik Gudbergsen
- Sponsor type
- Other
- Enrollment
- 150
- Started
- 2016-11
- Primary completion
- 2019-02 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in the degree of inflammation in the knee-joint (Greyscale-score)
Conditions studied
Osteoarthritis · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.